Developer docs
API playgroundTry for free, no card

Search company profiles

Visen Pharmaceuticals

Full company profile

uuid0004yb5

Namestring
Visen Pharmaceuticals
Legal namestring
维昇药业
Websiteurl
visenpharma.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Visen Pharmaceuticals (维昇药业, 2561.HK) is a Greater China-focused biopharmaceutical company founded in November 2018 by Ascendis Pharma A/S (Nasdaq: ASND) and Vivo Capital, with Sofinnova Ventures participating in the founding round. The company holds an exclusive license from Ascendis to develop and commercialize TransCon (Transient Conjugation) technology-based endocrine therapies across mainland China, Hong Kong, Macau, and Taiwan. Visen is headquartered in Suzhou with offices in Shanghai, Beijing, Hong Kong, and Taipei, employs 51-100 staff, and listed on the Hong Kong Stock Exchange Main Board on March 21, 2025, following a $150 million Series B round in January 2021 led by Sequoia China Fund.

Visen operates a platform-plus-product model built on the TransCon technology, which temporarily connects carrier molecules with biologically active parent drugs through a cleavable linker, enabling programmable release of unmodified active drug with extended dosing intervals. The pipeline comprises three lead assets: lonapegsomatropin (TransCon hGH / 维臻高®), a once-weekly long-acting growth hormone that received NMPA approval in January 2026 for pediatric growth hormone deficiency (GHD); palopegteriparatide (TransCon PTH), a prodrug restoring 24-hour physiological PTH levels for adult hypoparathyroidism, with Hainan Boao early-access approval in September 2025; and navepegritide (TransCon CNP), a weekly C-type natriuretic peptide therapy in Phase 2 development for achondroplasia. Lonapegsomatropin is the only long-acting growth hormone proven superior to daily formulations in head-to-head Phase 3 trials (heiGHt and briGHt).

Visen's revenue model combines pharmaceutical product sales with licensing economics under the Ascendis arrangement. Commercialization in China is executed through a layered channel-partner architecture: Shanghai Pharmaceuticals for national import and distribution, Anke Bio for regional promotion of lonapegsomatropin, Unique Healthcare and Harmony Healthcare for non-public and premium medical channels, and WuXi Biologics for technology transfer and localized manufacturing at a Chengdu dual-chamber lyophilization production line capable of over 10 million vials annually. End customers are dispersed patient populations across pediatric endocrinology (GHD), adult endocrinology (hypoparathyroidism with an estimated 400,000+ addressable patients in China), and pediatric rare disease (achondroplasia with ~50,000 patients in China), reached via hospitals and specialty clinics. Pricing is not publicly disclosed, and the company remains in very early commercialization following the January 2026 lonapegsomatropin approval.

Short descriptiontext

Visen Pharmaceuticals (2561.HK) is a Greater China biopharmaceutical company commercializing endocrine therapies based on the TransCon drug delivery platform licensed from Ascendis Pharma, targeting pediatric growth hormone deficiency, adult hypoparathyroidism, and pediatric achondroplasia across mainland China, Hong Kong, Macau, and Taiwan.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
endocrine therapeutics, growth hormone therapy, biopharmaceutical products, rare disease drugs, TransCon technology platform
Industry3 codes
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Endocrine Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Visen Pharmaceuticals generates revenue through sales of innovative endocrine drugs in the Greater China market. The company's first commercial product, lonapegsomatropin (维臻高/维昇高), received NMPA approval in January 2026 and is being commercialized through partnerships with distributors and promotion companies.

visenpharma.com
2Licensing and Royalty Income
TypeLicensing Royalties
Description

Visen holds exclusive rights from Ascendis Pharma to develop and commercialize endocrine treatments in Greater China (mainland China, Hong Kong, Macau, Taiwan). Revenue is generated through product sales under these licensing arrangements.

visenpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1维臻高®
Description

注射用隆培生长激素品牌名称,用于治疗儿童生长激素缺乏症

visenpharma.com
Core offering1 text field

Visen Pharmaceuticals develops and commercializes innovative endocrine therapeutics in the Greater China region under an exclusive license to Ascendis Pharma's TransCon technology platform. Its portfolio addresses growth hormone deficiency (GHD), hypoparathyroidism, and achondroplasia through long-acting prodrug formulations that enable weekly dosing instead of daily injections. The company's first commercial product, Lonapegsomatropin (维臻高®), received NMPA approval in January 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Lonapegsomatropin achieved 10.66 cm/year vs 9.75 cm/year (daily comparator) annual height velocity at 52 weeks (p=0.0010) in China briGHt Phase 3 trial
+3 more records
Product overview1 text field

VISEN Pharmaceuticals (维昇药业) is an innovative biopharmaceutical company specializing in endocrine-related therapies. The company operates a platform-plus-products model, with its TransCon technology platform serving as the foundation for three core commercial and near-commercial products: 维臻高®/隆培生长激素 (Lonapegsomatropin) for growth hormone deficiency, 帕罗培特立帕肽 (Palopegteriparatide) for hypoparathyroidism, and 那韦培肽 (Navepegritide) for achondroplasia. The company focuses on adult endocrinology, pediatric endocrinology, and rare endocrine diseases, with products addressing growth hormone deficiency, hypoparathyroidism, and achondroplasia.

Product and service4 records
1TransCon Technology Platform (TransCon 技术平台)
CategoryTechnology Platform
Description

Proprietary drug delivery technology platform that temporarily connects carrier molecules with biologically active parent drugs via a unique linker structure, enabling controlled release of unmodified parent drugs at programmable rates. Supports systemic and local delivery for proteins, peptides, and small molecules. Licensed exclusively from Ascendis Pharma for the Greater China region.

2维臻高® / Lonapegsomatropin (TransCon hGH, 注射用隆培生长激素)
CategoryPediatric Endocrinology Pharmaceutical Product
Description

Long-acting growth hormone (LAGH) administered once weekly for treatment of pediatric growth hormone deficiency (GHD). Uses TransCon technology to release unmodified human growth hormone with natural 22kDa structure. The only long-acting growth hormone proven superior to daily formulations in head-to-head Phase 3 trials (heiGHt and briGHt); briGHt China Phase 3 showed 10.66 cm/year vs 9.75 cm/year annual height velocity at 52 weeks (p=0.0010). 6-month room temperature storage stability.

3Palopegteriparatide (帕罗培特立帕肽, TransCon PTH)
CategoryAdult Endocrinology Pharmaceutical Product
Description

TransCon PTH prodrug designed to restore physiological PTH levels throughout 24 hours for treatment of adult chronic hypoparathyroidism. First hormone replacement therapy for this indication, addressing all aspects of the disease including normalizing blood calcium, urinary calcium, and blood phosphorus levels. Approved in EU (November 2023), UK MHRA (June 2024), and US FDA (August 2024).

4Navepegritide (那韦培肽, TransCon CNP)
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-27
Description

Strategic partnership for commercialization of lonapegsomatropin through non-public medical services. Unique Healthcare (2677.HK) provides standardized clinical application and full-cycle health services using their network of 20+ facilities and 400+ physicians.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2026-02-05
Description

Long-term strategic partnership for AI-powered drug discovery. XtalPi (2228.HK) provides AI and robot laboratory platform for early-stage R&D. Partnership valued at tens of millions of RMB, focusing on endocrine/metabolic therapeutic areas.

3Dongfu Long Technology Group (东富龙科技集团)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-06
Description

Strategic partnership for dual-chamber lyophilization technology development. Dongfu Long (300171.SZ) is a leading pharmaceutical equipment provider, collaborating to build China's first commercial dual-chamber lyophilization production line.

visenpharma.com
4Lingang New Area Management Committee (临港新片区管委会)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

Industrial cooperation agreement signed at CIIE 2025. Partnership with Shanghai Free Trade Zone Lingang New Area for local production, customs clearance, and business development support.

visenpharma.com
5Lingang Group (临港集团物贸平台)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

Industrial collaboration for supply chain and logistics optimization, leveraging Lingang Group's port and bonded zone resources for import/export services.

visenpharma.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-14
Description

Strategic cooperation framework for commercialization of lonapegsomatropin. Anke Bio (300009.SZ) authorized for exclusive promotion in specific regions of China, leveraging their 30+ years of biotech experience and 20+ year sales team.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

Strategic cooperation for market access and patient services in the premium healthcare segment in China.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-12-18
Description

Technology transfer and localized production partnership. WuXi Biologics (2269.HK) handles commercial manufacturing technology transfer for lonapegsomatropin, including construction of China's first dual-chamber lyophilization production line at Chengdu site.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-12-08
Description

Partnership for China's first large-scale hypoparathyroidism disease registry study (PaTHway R). Study enrolled 500+ patients across multiple centers to understand disease epidemiology and burden in China.

10Shanghai Pharmaceuticals (上海医药)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-11-01
Description

Strategic partnership for innovative drug lifecycle services. Shanghai Pharmaceuticals' subsidiary Shangphar International provides bonded import, national distribution, supply chain optimization, and innovative value-added services for VISEN's commercialized products in mainland China.

visenpharma.com
11China Alliance for Rare Disease (中国罕见病联盟)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-09-27
Description

Strategic cooperation for achondroplasia research and awareness. Supported ApproaCH epidemiological study covering 14 centers and ~500 patients. Renewed partnership in May 2025 expanding to broader pediatric growth and development field.

visenpharma.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2018-11-07
Description

Ascendis Pharma (Nasdaq: ASND) is the parent company and technology licensor. Founded in Denmark, Ascendis granted VISEN exclusive rights to develop and commercialize TransCon-based endocrine products in Greater China (mainland China, Hong Kong, Macau, Taiwan). VISEN was established in 2018 with Ascendis and Vivo Capital as founding investors.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BioMarin commercializes Voxzogo (vosoritide), the first FDA-approved CNP therapy for achondroplasia, and is the closest global competitor to Visen's navepegritide in achondroplasia. Both target the FGFR3 pathway with CNP analogues for the same rare skeletal dysplasia indication.

TypeBroad incumbent
Description

Lilly markets Humatrope (somatropin) and has a broad endocrinology/metabolic portfolio. As a global incumbent in pediatric and adult endocrine disorders, Lilly is a relevant competitor across Visen's therapeutic areas.

TypeBroad incumbent
Description

Novo Nordisk markets Norditropin, a leading daily growth hormone with established global and China presence. Its broad endocrine and metabolic portfolio (including Sogroya, a competing long-acting GH) makes it a major incumbent across Visen's endocrinology indications.

TypeBroad incumbent
Description

Pfizer commercializes Genotropin, one of the legacy global pediatric growth hormone brands. As a broad pharma incumbent with established Chinese commercial infrastructure, Pfizer represents an entrenched competitor in pediatric GHD.

TypeBroad incumbent
Description

Takeda commercializes Natpara/Natrel (parathyroid hormone), the legacy treatment for hypoparathyroidism in the US. As a broad rare disease and endocrine player, Takeda competes directly with Visen's palopegteriparatide in the hypoparathyroidism space.

TypeDirect peer
Description

Ascendis Pharma is the originator and licensor of the TransCon technology platform used across Visen's entire pipeline. Both companies develop TransCon-based endocrine therapies (hGH, PTH, CNP) using the same prodrug conjugation technology, making them the closest direct peer despite different geographies.

TypeDirect peer
Description

Anhui Anke is a leading Chinese pediatric growth hormone producer and is also Visen's regional promotion partner. Its established domestic GH franchise (安苏萌) creates direct overlap with lonapegsomatropin in hospital and clinic channels across China.

TypeDirect peer
Description

GenScience is one of China's largest domestic pediatric growth hormone manufacturers (via subsidiary Changchun GenSci), directly competing with lonapegsomatropin in the pediatric GHD market. Both target the same Chinese pediatric endocrinology prescribers with daily and long-acting GH products.

TypeEmerging player
Description

Theratechnologies is a specialty endocrine biopharma focused on growth hormone-releasing peptide therapies (tesamorelin) for HIV-related lipodystrophy and other endocrine conditions. It is comparable to Visen as a smaller, specialty-focused endocrine company with similar revenue scale.

TypeDirect peer
Description

Ipsen has global rights to palopegteriparatide (TransCon PTH) for hypoparathyroidism outside Greater China and is currently launching the same molecule in EU/UK/US markets. Both Ipsen and Visen commercialize the identical Ascendis-licensed endocrine asset in their respective territories.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Visen Pharmaceuticals

Endocrine Pharmaceuticalsvisenpharma.com

Visen Pharmaceuticals (2561.HK) is a Greater China biopharmaceutical company commercializing endocrine therapies based on the TransCon drug delivery platform licensed from Ascendis Pharma, targeting pediatric growth hormone deficiency, adult hypoparathyroidism, and pediatric achondroplasia across mainland China, Hong Kong, Macau, and Taiwan.

What Visen Pharmaceuticals does

Visen Pharmaceuticals (维昇药业, 2561.HK) is a Greater China-focused biopharmaceutical company founded in November 2018 by Ascendis Pharma A/S (Nasdaq: ASND) and Vivo Capital, with Sofinnova Ventures participating in the founding round. The company holds an exclusive license from Ascendis to develop and commercialize TransCon (Transient Conjugation) technology-based endocrine therapies across mainland China, Hong Kong, Macau, and Taiwan. Visen is headquartered in Suzhou with offices in Shanghai, Beijing, Hong Kong, and Taipei, employs 51-100 staff, and listed on the Hong Kong Stock Exchange Main Board on March 21, 2025, following a $150 million Series B round in January 2021 led by Sequoia China Fund.

Visen operates a platform-plus-product model built on the TransCon technology, which temporarily connects carrier molecules with biologically active parent drugs through a cleavable linker, enabling programmable release of unmodified active drug with extended dosing intervals. The pipeline comprises three lead assets: lonapegsomatropin (TransCon hGH / 维臻高®), a once-weekly long-acting growth hormone that received NMPA approval in January 2026 for pediatric growth hormone deficiency (GHD); palopegteriparatide (TransCon PTH), a prodrug restoring 24-hour physiological PTH levels for adult hypoparathyroidism, with Hainan Boao early-access approval in September 2025; and navepegritide (TransCon CNP), a weekly C-type natriuretic peptide therapy in Phase 2 development for achondroplasia. Lonapegsomatropin is the only long-acting growth hormone proven superior to daily formulations in head-to-head Phase 3 trials (heiGHt and briGHt).

Visen's revenue model combines pharmaceutical product sales with licensing economics under the Ascendis arrangement. Commercialization in China is executed through a layered channel-partner architecture: Shanghai Pharmaceuticals for national import and distribution, Anke Bio for regional promotion of lonapegsomatropin, Unique Healthcare and Harmony Healthcare for non-public and premium medical channels, and WuXi Biologics for technology transfer and localized manufacturing at a Chengdu dual-chamber lyophilization production line capable of over 10 million vials annually. End customers are dispersed patient populations across pediatric endocrinology (GHD), adult endocrinology (hypoparathyroidism with an estimated 400,000+ addressable patients in China), and pediatric rare disease (achondroplasia with ~50,000 patients in China), reached via hospitals and specialty clinics. Pricing is not publicly disclosed, and the company remains in very early commercialization following the January 2026 lonapegsomatropin approval.

Visen Pharmaceuticals firmographics

Firmographics
Name
Visen Pharmaceuticals
Legal name
维昇药业
Website
https://visenpharma.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Visen Pharmaceuticals (2561.HK) is a Greater China biopharmaceutical company commercializing endocrine therapies based on the TransCon drug delivery platform licensed from Ascendis Pharma, targeting pediatric growth hormone deficiency, adult hypoparathyroidism, and pediatric achondroplasia across mainland China, Hong Kong, Macau, and Taiwan.
Ownership category
akta.pro rank

Visen Pharmaceuticals industry classification

Industry
Product category
Endocrine Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Endocrine therapeutics
  • Growth hormone therapy
  • Biopharmaceutical products
  • Rare disease drugs
  • TransCon technology platform

Where Visen Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices5 records

Markets served

Visen Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others

Revenue model

  1. Pharmaceutical Product Sales: Visen Pharmaceuticals generates revenue through sales of innovative endocrine drugs in the Greater China market. The company's first commercial product, lonapegsomatropin (维臻高/维昇高), received NMPA approval in January 2026 and is being commercialized through partnerships with distributors and promotion companies.
  2. Licensing and Royalty Income: Visen holds exclusive rights from Ascendis Pharma to develop and commercialize endocrine treatments in Greater China (mainland China, Hong Kong, Macau, Taiwan). Revenue is generated through product sales under these licensing arrangements.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Visen Pharmaceuticals product offering

Product offering

Core offering

Visen Pharmaceuticals develops and commercializes innovative endocrine therapeutics in the Greater China region under an exclusive license to Ascendis Pharma's TransCon technology platform. Its portfolio addresses growth hormone deficiency (GHD), hypoparathyroidism, and achondroplasia through long-acting prodrug formulations that enable weekly dosing instead of daily injections. The company's first commercial product, Lonapegsomatropin (维臻高®), received NMPA approval in January 2026.

Product overview

VISEN Pharmaceuticals (维昇药业) is an innovative biopharmaceutical company specializing in endocrine-related therapies. The company operates a platform-plus-products model, with its TransCon technology platform serving as the foundation for three core commercial and near-commercial products: 维臻高®/隆培生长激素 (Lonapegsomatropin) for growth hormone deficiency, 帕罗培特立帕肽 (Palopegteriparatide) for hypoparathyroidism, and 那韦培肽 (Navepegritide) for achondroplasia. The company focuses on adult endocrinology, pediatric endocrinology, and rare endocrine diseases, with products addressing growth hormone deficiency, hypoparathyroidism, and achondroplasia.

Differentiator

Problem solved

Functional benefit

Brands

  • 维臻高®: 注射用隆培生长激素品牌名称,用于治疗儿童生长激素缺乏症

Products and services

  • TransCon Technology Platform (TransCon 技术平台) Proprietary drug delivery technology platform that temporarily connects carrier molecules with biologically active parent drugs via a unique linker structure, enabling controlled release of unmodified parent drugs at programmable rates. Supports systemic and local delivery for proteins, peptides, and small molecules. Licensed exclusively from Ascendis Pharma for the Greater China region.
  • 维臻高® / Lonapegsomatropin (TransCon hGH, 注射用隆培生长激素) Long-acting growth hormone (LAGH) administered once weekly for treatment of pediatric growth hormone deficiency (GHD). Uses TransCon technology to release unmodified human growth hormone with natural 22kDa structure. The only long-acting growth hormone proven superior to daily formulations in head-to-head Phase 3 trials (heiGHt and briGHt); briGHt China Phase 3 showed 10.66 cm/year vs 9.75 cm/year annual height velocity at 52 weeks (p=0.0010). 6-month room temperature storage stability.
  • Palopegteriparatide (帕罗培特立帕肽, TransCon PTH) TransCon PTH prodrug designed to restore physiological PTH levels throughout 24 hours for treatment of adult chronic hypoparathyroidism. First hormone replacement therapy for this indication, addressing all aspects of the disease including normalizing blood calcium, urinary calcium, and blood phosphorus levels. Approved in EU (November 2023), UK MHRA (June 2024), and US FDA (August 2024).
  • Navepegritide (那韦培肽, TransCon CNP)

Quantifiable outcome

  • Lonapegsomatropin achieved 10.66 cm/year vs 9.75 cm/year (daily comparator) annual height velocity at 52 weeks (p=0.0010) in China briGHt Phase 3 trial
  • +3 more outcomes

Companies that use Visen Pharmaceuticals

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Visen Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Visen Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered major and core.

  • Unique Healthcare (卓正医疗)majorChannel Partner/ Reseller/ Distributor · 27 May 2026Strategic partnership for commercialization of lonapegsomatropin through non-public medical services. Unique Healthcare (2677.HK) provides standardized clinical application and full-cycle health services using their network of 20+ facilities and 400+ physicians.
  • XtalPi (晶泰科技)majorTechnology or Integration · 5 February 2026Long-term strategic partnership for AI-powered drug discovery. XtalPi (2228.HK) provides AI and robot laboratory platform for early-stage R&D. Partnership valued at tens of millions of RMB, focusing on endocrine/metabolic therapeutic areas.
  • Dongfu Long Technology Group (东富龙科技集团)coreTechnology or Integration · 6 November 2025Strategic partnership for dual-chamber lyophilization technology development. Dongfu Long (300171.SZ) is a leading pharmaceutical equipment provider, collaborating to build China's first commercial dual-chamber lyophilization production line.
  • Lingang New Area Management Committee (临港新片区管委会)majorStrategic or Co-development Partner · 6 November 2025Industrial cooperation agreement signed at CIIE 2025. Partnership with Shanghai Free Trade Zone Lingang New Area for local production, customs clearance, and business development support.
  • Lingang Group (临港集团物贸平台)majorStrategic or Co-development Partner · 6 November 2025Industrial collaboration for supply chain and logistics optimization, leveraging Lingang Group's port and bonded zone resources for import/export services.
  • Anke Bio (安科生物)coreChannel Partner/ Reseller/ Distributor · 14 July 2025Strategic cooperation framework for commercialization of lonapegsomatropin. Anke Bio (300009.SZ) authorized for exclusive promotion in specific regions of China, leveraging their 30+ years of biotech experience and 20+ year sales team.
  • Harmony Healthcare (和睦家医疗)majorChannel Partner/ Reseller/ Distributor · 1 January 2024Strategic cooperation for market access and patient services in the premium healthcare segment in China.
  • WuXi Biologics (药明生物)coreImplementation/ SI/ Consulting Partner · 18 December 2023Technology transfer and localized production partnership. WuXi Biologics (2269.HK) handles commercial manufacturing technology transfer for lonapegsomatropin, including construction of China's first dual-chamber lyophilization production line at Chengdu site.
  • Peking University Clinical Research Institute (北京大学临床研究所)majorStrategic or Co-development Partner · 8 December 2023Partnership for China's first large-scale hypoparathyroidism disease registry study (PaTHway R). Study enrolled 500+ patients across multiple centers to understand disease epidemiology and burden in China.
  • Shanghai Pharmaceuticals (上海医药)coreChannel Partner/ Reseller/ Distributor · 1 November 2023Strategic partnership for innovative drug lifecycle services. Shanghai Pharmaceuticals' subsidiary Shangphar International provides bonded import, national distribution, supply chain optimization, and innovative value-added services for VISEN's commercialized products in mainland China.
  • China Alliance for Rare Disease (中国罕见病联盟)majorStrategic or Co-development Partner · 27 September 2020Strategic cooperation for achondroplasia research and awareness. Supported ApproaCH epidemiological study covering 14 centers and ~500 patients. Renewed partnership in May 2025 expanding to broader pediatric growth and development field.
  • Ascendis Pharma A/ScoreOEM/ Whitelabel/ Licensing Partner · 7 November 2018Ascendis Pharma (Nasdaq: ASND) is the parent company and technology licensor. Founded in Denmark, Ascendis granted VISEN exclusive rights to develop and commercialize TransCon-based endocrine products in Greater China (mainland China, Hong Kong, Macau, Taiwan). VISEN was established in 2018 with Ascendis and Vivo Capital as founding investors.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Visen Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • BioMarin Pharmaceutical: BioMarin commercializes Voxzogo (vosoritide), the first FDA-approved CNP therapy for achondroplasia, and is the closest global competitor to Visen's navepegritide in achondroplasia. Both target the FGFR3 pathway with CNP analogues for the same rare skeletal dysplasia indication.
  • Ascendis Pharma A/S: Ascendis Pharma is the originator and licensor of the TransCon technology platform used across Visen's entire pipeline. Both companies develop TransCon-based endocrine therapies (hGH, PTH, CNP) using the same prodrug conjugation technology, making them the closest direct peer despite different geographies.
  • Anhui Anke Biotechnology Group: Anhui Anke is a leading Chinese pediatric growth hormone producer and is also Visen's regional promotion partner. Its established domestic GH franchise (安苏萌) creates direct overlap with lonapegsomatropin in hospital and clinic channels across China.
  • GenScience Pharmaceutical (长春高新): GenScience is one of China's largest domestic pediatric growth hormone manufacturers (via subsidiary Changchun GenSci), directly competing with lonapegsomatropin in the pediatric GHD market. Both target the same Chinese pediatric endocrinology prescribers with daily and long-acting GH products.
  • Ipsen: Ipsen has global rights to palopegteriparatide (TransCon PTH) for hypoparathyroidism outside Greater China and is currently launching the same molecule in EU/UK/US markets. Both Ipsen and Visen commercialize the identical Ascendis-licensed endocrine asset in their respective territories.

Broad incumbents

  • Eli Lilly: Lilly markets Humatrope (somatropin) and has a broad endocrinology/metabolic portfolio. As a global incumbent in pediatric and adult endocrine disorders, Lilly is a relevant competitor across Visen's therapeutic areas.
  • Novo Nordisk: Novo Nordisk markets Norditropin, a leading daily growth hormone with established global and China presence. Its broad endocrine and metabolic portfolio (including Sogroya, a competing long-acting GH) makes it a major incumbent across Visen's endocrinology indications.
  • Pfizer (via Hospira/legacy): Pfizer commercializes Genotropin, one of the legacy global pediatric growth hormone brands. As a broad pharma incumbent with established Chinese commercial infrastructure, Pfizer represents an entrenched competitor in pediatric GHD.
  • Takeda Pharmaceutical: Takeda commercializes Natpara/Natrel (parathyroid hormone), the legacy treatment for hypoparathyroidism in the US. As a broad rare disease and endocrine player, Takeda competes directly with Visen's palopegteriparatide in the hypoparathyroidism space.

Emerging players

  • Theratechnologies: Theratechnologies is a specialty endocrine biopharma focused on growth hormone-releasing peptide therapies (tesamorelin) for HIV-related lipodystrophy and other endocrine conditions. It is comparable to Visen as a smaller, specialty-focused endocrine company with similar revenue scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Visen Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Visen Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles11 records

Visen Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Visen Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Visen Pharmaceuticals

What does Visen Pharmaceuticals do?

Visen Pharmaceuticals develops and commercializes innovative endocrine therapeutics in the Greater China region under an exclusive license to Ascendis Pharma's TransCon technology platform. Its portfolio addresses growth hormone deficiency (GHD), hypoparathyroidism, and achondroplasia through long-acting prodrug formulations that enable weekly dosing instead of daily injections. The company's first commercial product, Lonapegsomatropin (维臻高®), received NMPA approval in January 2026.

Is Visen Pharmaceuticals a public or private company?

Visen Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Visen Pharmaceuticals founded?

Visen Pharmaceuticals was founded in 2018. It employs 11 to 50 people.

Where is Visen Pharmaceuticals based?

Visen Pharmaceuticals is headquartered in Shanghai, China, in the Asia region.

How does Visen Pharmaceuticals make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Royalty Income.

Who are Visen Pharmaceuticals's main competitors?

Direct peers on record are BioMarin Pharmaceutical, Ascendis Pharma A/S, Anhui Anke Biotechnology Group, GenScience Pharmaceutical (长春高新) and Ipsen. Broad incumbents are Eli Lilly, Novo Nordisk, Pfizer (via Hospira/legacy) and Takeda Pharmaceutical. Theratechnologies is listed as an emerging player.

Does Visen Pharmaceuticals have an API?

No public API is recorded for Visen Pharmaceuticals.

What industry is Visen Pharmaceuticals in?

Visen Pharmaceuticals's product category is Endocrine Pharmaceuticals. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACXtalPi Holdings Announces 2026 Interim ResultsXtalPi Holdings reported H1 2026 revenue of RMB393.6 million, down from RMB517.1 million, and a net loss of RMB224.9 million. The revenue decline was due to a high base from a US$51 million upfront payment, while excluding that impact revenue rose 73.8% year-on-year. The company expects over 10 pipelines in clinical stage by 2027.医药魔方-致力于数据赋能医药创新,助力高效决策与数智化转型Interview: How Visen Pharma's JV Model Cracked the China Biopharma MarketVisen Pharmaceuticals listed on the Hong Kong Stock Exchange on 21 March, oversubscribed over 70-fold. The company raised HKD 672 million, with most funds allocated to commercialisation of its long-acting growth hormone Skytrofa, whose BLA was accepted a year prior. The JV incubation model with Ascendis Pharma enabled rapid milestone completion without milestone payments.PR NewswireDouble-blind period completes! Primary endpoint analysis of phase 3 clinical trial to be conducted for China's first hormone replacement treatment targeting hypoparathyroidismVISEN Pharmaceuticals has completed the double-blind period of its Phase 3 clinical trial for palopegteriparatide, an investigational hormone replacement therapy for hypoparathyroidism in China. The company plans to analyze primary endpoints and submit a New Drug Application (NDA) to the National Medical Products Administration (NMPA) by early 2023. This development marks a significant step toward potentially launching China's first specific treatment for this rare endocrine disorder.PR NewswireVISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of LonapegsomatropinVISEN Pharmaceuticals disclosed Phase 3 trial data for lonapegsomatropin in Chinese children with growth hormone deficiency, showing an annualized height velocity of 10.66 cm/year versus 9.75 cm/year for daily hGH at 52 weeks. The treatment difference was 0.91 cm/year (p=0.0010), meeting the non-inferiority objective. The company stated lonapegsomatropin is currently the only long-acting growth hormone demonstrating superiority to daily hGH in China.PR NewswireVISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth HormoneVISEN Pharmaceuticals announced positive top-line results from its pivotal Phase 3 trial comparing once-weekly lonapegsomatropin (TransCon hGH) to daily growth hormone in children with growth hormone deficiency in China. The trial met its primary objective, demonstrating superior efficacy on annualized height velocity at 52 weeks (p=0.0010) with comparable safety and tolerability. VISEN Pharmaceuticals plans to submit a Biologic License Application to China's National Medical Products Administration, holding exclusive rights to develop and commercialize the drug in Greater China.Caixin GlobalChinese Biotech Firm VISEN Raises $150m Led by Sequoia Capital ChinaVISEN Pharmaceuticals raised $150 million in a Series B round led by Sequoia Capital China. The funding will accelerate clinical development, manufacturing, and commercialization of its three products in Greater China. The company aims to expand its pipeline through international partnerships.FinSMEsVisen Pharmaceuticals Closes $150M Series B FinancingVisen Pharmaceuticals closed a $150M Series B financing led by Sequoia China, with participation from multiple investors. The funds will accelerate clinical development of its endocrine drug candidates, including the ongoing Phase 3 study of TransCon hGH in China.PR NewswireVISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater ChinaVISEN Pharmaceuticals announced the closing of a $150 million Series B financing round led by Sequoia China with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, CDG Capital, and existing investors including Ascendis Pharma, Vivo Capital, and Sofinnova Investments. Proceeds will accelerate clinical development and commercialization of the company's three endocrinology drug candidates, including TransCon hGH which is currently in Phase 3 trials in China, with IND approval recently received for the ACcomplisH China Phase 2 study of TransCon CNP. VISEN Pharmaceuticals was formed in 2018 by Ascendis Pharma and Vivo Capital to develop and commercialize endocrinology therapies for the Greater China market.YahooAscendis Pharma A/S Announces Equity Investment in VISEN PharmaceuticalsAscendis Pharma announced a $12.5 million equity investment in VISEN Pharmaceuticals as part of VISEN's $150 million Series B financing. Ascendis retains approximately 44% of VISEN's shares and expects a non-cash gain in Q1 2021. The investment supports VISEN's development of TransCon endocrinology therapies in Greater China.